1045 related articles for article (PubMed ID: 30231896)
1. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
[TBL] [Abstract][Full Text] [Related]
3. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Cummings JL; Cohen S; van Dyck CH; Brody M; Curtis C; Cho W; Ward M; Friesenhahn M; Rabe C; Brunstein F; Quartino A; Honigberg LA; Fuji RN; Clayton D; Mortensen D; Ho C; Paul R
Neurology; 2018 May; 90(21):e1889-e1897. PubMed ID: 29695589
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
Guthrie H; Honig LS; Lin H; Sink KM; Blondeau K; Quartino A; Dolton M; Carrasco-Triguero M; Lian Q; Bittner T; Clayton D; Smith J; Ostrowitzki S
J Alzheimers Dis; 2020; 76(3):967-979. PubMed ID: 32568196
[TBL] [Abstract][Full Text] [Related]
5. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S; Bittner T; Sink KM; Mackey H; Rabe C; Honig LS; Cassetta E; Woodward M; Boada M; van Dyck CH; Grimmer T; Selkoe DJ; Schneider A; Blondeau K; Hu N; Quartino A; Clayton D; Dolton M; Dang Y; Ostaszewski B; Sanabria-Bohórquez SM; Rabbia M; Toth B; Eichenlaub U; Smith J; Honigberg LA; Doody RS
JAMA Neurol; 2022 Nov; 79(11):1113-1121. PubMed ID: 36121669
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
[TBL] [Abstract][Full Text] [Related]
8. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
[TBL] [Abstract][Full Text] [Related]
9. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.
Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR
J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321
[TBL] [Abstract][Full Text] [Related]
12. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
[TBL] [Abstract][Full Text] [Related]
13. Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid.
Yang T; Dang Y; Ostaszewski B; Mengel D; Steffen V; Rabe C; Bittner T; Walsh DM; Selkoe DJ
Ann Neurol; 2019 Aug; 86(2):215-224. PubMed ID: 31168802
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G
J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523
[TBL] [Abstract][Full Text] [Related]
15. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
[TBL] [Abstract][Full Text] [Related]
16. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
[TBL] [Abstract][Full Text] [Related]
18. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
[TBL] [Abstract][Full Text] [Related]
19. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]